This study investigates MTAP-deleted solid tumors. It explores how the investigational medication, BAY 3713372, works in treating this condition.
The study evaluates the safety, processing by the body, and effectiveness of BAY 3713372 in participants with MTAP-deleted solid tumors.
- Who can participate: Adults aged 18 or older with MTAP-deleted solid tumors and a performance status of 0 or 1 may participate. Participants must have measurable lesions and meet specific health criteria.
- Study details: Participants will receive the investigational medication, BAY 3713372. They may also receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last until 2 years after the last participant's last dose or the end of the study.